findmyKOL

Vivek Subbiah, MD

Enriched profile

Professor of Medicine (Oncology) and Professor of Pediatrics (Hematology/Oncology); Jeffrey and Christina Bird Professor; Associate Director for Drug Development and Precision Oncology, Stanford Cancer Institute · Stanford University School of Medicine

ORCIDNPI
RegionStanford, CA · WestSpecialtyMedical OncologyFocusCancer Genomics and Diagnostics+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Vivek Subbiah is Professor of Medicine (Oncology) and Professor of Pediatrics (Hematology/Oncology); Jeffrey and Christina Bird Professor; Associate Director for Drug Development and Precision Oncology, Stanford Cancer Institute at Stanford University School of Medicine. OpenAlex indexes 1,434 publications with 32,217 citations (h-index 79); ClinicalTrials.gov lists 16 registered studies with this person as an investigator.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

Vivek Subbiah is Professor of Medicine (Oncology) and Professor of Pediatrics (Hematology/Oncology) at Stanford University School of Medicine / Stanford Cancer Institute (Division of Oncology, Department of Medicine). The public record shows 1,434 publications with 32,217 citations (h-index 79), centered on Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Sarcoma Diagnosis and Treatment. It also documents an investigator role on 12 registered clinical trials.

  • Most recent indexed publication: 2026 · Cancer biotherapy & radiopharmaceuticals
  • Top research focus: Cancer Genomics and Diagnostics
  • 12 registered trials on ClinicalTrials.gov

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lymphoma3 trialsSarcoma2 trialsMultiple Myeloma2 trialsPancreatic Cancer2 trialsComa2 trialsHepatobiliary Cancer2 trialsHead & Neck Cancer2 trialsCholangiocarcinoma2 trialsLung Cancer (NSCLC/SCLC)1 trialColorectal Cancer1 trialBreast Cancer1 trialProstate Cancer1 trialBladder / Urothelial Cancer1 trialKidney Cancer / RCC1 trialGastroesophageal Cancer1 trialOvarian / Gynecologic Cancer1 trialMelanoma1 trialLeukemia (AML/ALL/CML/CLL)1 trialNeuro-Oncology / Glioma1 trialLeukemia, Myeloid, Acute1 trialStomach Neoplasms1 trialPrecursor Cell Lymphoblastic Leukemia-Lymphoma1 trialColonic Neoplasms1 trialUterine Cervical Neoplasms1 trialRectal Neoplasms1 trialEsophageal Neoplasms1 trialHodgkin Disease1 trialLiver Neoplasms1 trialKidney Neoplasms1 trialFallopian Tube Neoplasms1 trialAstrocytoma1 trialNasopharyngeal Carcinoma1 trialSkin Neoplasms1 trialNeuroendocrine Tumors1 trialWaldenstrom Macroglobulinemia1 trialSexually Transmitted Diseases1 trialMesothelioma1 trialTesticular Neoplasms1 trialAnus Neoplasms1 trialLaryngeal Neoplasms1 trialBone Neoplasms1 trialBile Duct Neoplasms1 trialUterine Neoplasms1 trialSalivary Gland Neoplasms1 trialVulvar Neoplasms1 trialLiposarcoma1 trialPheochromocytoma1 trialSarcoma, Kaposi1 trialVaginal Neoplasms1 trialSarcoma, Synovial1 trialTongue Neoplasms1 trialCarcinoid Tumor1 trialNeoplasms, Unknown Primary1 trialPenile Neoplasms1 trialChondrosarcoma1 trialAppendiceal Neoplasms1 trialUreteral Neoplasms1 trialCarcinoma, Adenoid Cystic1 trialParathyroid Neoplasms1 trialAdrenal Gland Neoplasms1 trialCarcinoma, Small Cell1 trialThymus Neoplasms1 trialCysts1 trialMultiple Endocrine Neoplasia1 trialBrain Stem Neoplasms1 trialTrophoblastic Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsSarcoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Drugs & molecules

across trials, industry payments and publications
Keytrudageneric · PembrolizumabClinical trials1Industry payments3Publications3Retevmogeneric · SelpercatinibClinical trialsIndustry payments2Publications11Gavretogeneric · PralsetinibClinical trialsIndustry payments3Publications8

Works with

trial sponsors and companies reporting payments
E.R. Squibb & Sons, L.L.C.Clinical trialsIndustry payments22Pfizer Inc.Clinical trialsIndustry payments16Novartis Pharmaceuticals CorporationClinical trialsIndustry payments14

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,434publications

Distinct works indexed by OpenAlex, matched via ORCID; 142 in PubMed.

32,217citations

Total citations across indexed works.

79h-index

Hirsch index (OpenAlex). i10-index 405.

Clinical & industry

trials, payments and federal funding
16clinical trials

Investigator role on registered studies.

View trials
43companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

43 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    100%
    Corticosteroid100%
    Dexamethasone sodium phosphate100%
    Part B, office-administered13 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/vivek-subbiah-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • Instagram

    instagram.com/viveksubbiahmd

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com
  • LinkedIn

    linkedin.com/in/vivek-subbiah-md-bb968633

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
4 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Other

    esmo.org/about-esmo/biographies/vivek-subbiah

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →esmo.org
  • Other

    onclive.com/authors/vivek-subbiah-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com
2 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Co-Chair

    'Advances in Precision Oncology' Clinical Trials Mini Symposium, AACR Annual Meeting 2026

    2026
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com
  • Member

    ESMO Precision Oncology Working Group

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com
  • Leadership/committee involvement in ASCO

    AACR, and ESMO (tumor-agnostic precision oncology programming)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com

Awards & honors

honors on the public record
2 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Former: Chief

    Early-Phase Drug Development, Sarah Cannon Research Institute

    2026
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scri.com
  • Former: Associate Professor

    Department of Investigational Cancer Therapeutics, and Medical Director, Clinical Center for Targeted Therapy, UT MD Anderson Cancer Center

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu
1 more affiliation behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
  • Host

    JAMA Oncology podcast episode with Dr. Michael Postow (Memorial Sloan Kettering) on immunotherapy for melanoma brain metastases (AMA Ed Hub platform)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com
  • Featured video/commentary contributor

    OncLive (tissue-agnostic therapies, precision oncology)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com
  • Featured interview

    AJMC - "AI Should Support Clinicians, Not Replace Them" (Patient-Centered Oncology Care conference)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.